Skip to content
DataLookout
Menu

NCT07816341

F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 10, 2026 to Oct 27, 2026
    • Site details revised
    • Study title shortened, about 4 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of adverse events
Timeframe: 28 days post the last dose treatment

Arms and interventions

F182112 in Relapsed/Refractory Autoimmune Hemolytic AnemiaExperimental

F182112 is a recombinant humanized anti-BCMA/CD3 bispecific antibody for injection. By binding to CD3 receptors on T cells, F182112 can effectively deplete BCMA-expressing B cells and plasma cells in vivo, thereby alleviating the clinical manifestations of autoimmune diseases.

Drugs: F182112 single-agent

Sites

1 site in 1 country

  • Red Blood Cell Diseases Center and Regenerative Medicine CenterTianjin, Tianjin Municipality, China